respect
strong
antivir
activ
phosphonomethoxi
propyl
variou
type
side
chain
fluorin
analogu
prepar
titl
compound
phosphonomethoxi
propyl
synthesis
condens
reaction
diisopropoxyphosphoryl
methoxi
ptoluenesulfon
sodium
salt
follow
separ
appropri
n
regioisom
ester
hydrolysi
transform
counterpart
amino
acid
phosphoramid
prodrug
system
annel
fivememb
imidazol
ring
ie
imidazo
triazin
deriv
also
carri
prepar
trifluoromethyloxiran
form
treat
diisopropyl
bromomethanephosphon
follow
deprotect
ester
antivir
activ
newli
prepar
compound
studi
diisopropyl
ester
inhibit
replic
herp
virus
ec
valu
three
time
higher
refer
antihcmv
drug
ganciclovir
without
display
cytotox
chemistri
acycl
nucleosid
phosphon
anp
key
research
topic
institut
organ
chemistri
biochemistri
pragu
import
compound
lie
biolog
activ
especi
antivir
three
compound
class
alreadi
becam
commerci
avail
drug
cidofovir
treatment
human
cytomegaloviru
cmv
retin
aid
patient
adefovir
prodrug
form
adefovir
dipivoxil
treatment
hepat
b
hbv
tenofovir
either
tenofovir
disoproxil
fumar
recent
sinc
also
new
prodrug
form
tenofovir
alafenamid
taf
treatment
hiv
hbv
infect
introduct
tenofovir
market
crucial
influenc
transform
hivaid
mortal
threat
manag
chronic
diseas
besid
longterm
systemat
investig
anp
enabl
develop
mani
therapeut
promis
structur
synthesis
never
advanc
stage
preclinicalclin
investig
among
other
concern
fluorin
purin
phosphonomethoxi
propyl
deriv
acycl
nucleosid
phosphon
base
moieti
anp
origin
synthesis
aim
search
new
epigenet
hypomethyl
agent
contrari
nucleosid
azacitidin
decitabin
howev
activ
found
evid
presenc
sugar
moieti
essenti
effect
hand
found
new
class
antivir
agent
select
dna
virus
lead
compound
group
analogu
cidofovir
phosphonomethoxi
propyl
fig
comparison
cidofovir
antivir
activ
data
similar
toxic
profil
favour
select
index
ratio
cytotox
concentr
cc
effect
concentr
ec
higher
cidofovir
antivir
activ
increas
mani
time
transform
ester
prodrug
deriv
cyclic
form
disadvantag
rather
complic
metabol
profil
caus
chemic
also
enzymat
instabl
therefor
compound
final
advanc
stage
clinic
investig
anp
better
stabil
either
inact
antivir
activ
margin
interestingli
eg
phosphonomethoxi
ethyl
deriv
exhibit
antivir
activ
convert
appropri
prodrug
studi
investig
new
type
anp
modifi
fluorin
acycl
part
fluorin
deriv
especi
nucleosid
nucleotid
analogu
compound
great
interest
introduct
fluorin
atom
biolog
activ
molecul
often
lead
remark
chang
physic
biolog
pharmacokinet
properti
due
electroneg
size
omniphob
lipophil
electrostat
interact
clinic
practic
fluorin
nucleosid
utilis
effect
cytostat
eg
gemcitabin
antivir
trifluridin
sofosbuvir
within
group
anp
phosphonomethoxi
propyl
fpmp
deriv
identifi
potent
select
inhibitor
retrovirus
adenin
deriv
phosphonomethoxi
propyl
adenin
fpmpa
exhibit
even
better
vivo
antihiv
antihbv
paramet
adefovir
activ
hiv
also
known
enantiom
phosphonomethoxi
propyl
fpmpdap
guanin
counterpart
structur
compound
depict
fig
paper
describ
synthesi
biolog
activ
sidechain
fluorin
analogu
deriv
modif
base
moieti
modif
design
aim
stabilis
ring
moreov
must
taken
account
anp
compound
bear
free
phosphon
group
polar
charact
respons
limit
intracellular
deliveri
low
oral
bioavail
usual
way
overcom
problem
transform
compound
appropri
prodrug
frequent
use
anp
prodrug
acyloxyalkyl
pivaloyloxymethyl
pom
alkyloxyalkyl
sacylthioethyl
sate
aryl
cyclic
cyclosaligenyl
phophon
ester
phosphoramid
bear
amino
acid
ester
protid
despit
promis
vitro
vivo
studi
proceed
clinic
trial
attribut
difficulti
achiev
right
prodrug
properti
balanc
particular
suitabl
chemic
stabil
rate
convers
safeti
respect
byproduct
avoid
stereoisom
adequ
physic
properti
abil
crystallis
solubl
abil
synthes
substanti
quantiti
synthesi
anp
prodrug
investig
pharmacolog
properti
subject
mani
review
regard
abovement
fact
transform
new
structur
prodrug
form
integr
part
work
logic
method
prepar
reveal
direct
condens
sodium
salt
appropri
fluorin
precursor
reactiv
precursor
diisopropoxyphosphoryl
methoxi
ptoluenesulphon
fpmp
synthon
methanesulphonyl
analogu
synthon
approach
alreadi
report
prepar
purin
fpmp
deriv
jindrich
et
al
synthesi
start
protect
oribonolacton
includ
mani
nine
reaction
step
anoth
effici
synthesi
fpmp
synthon
utilis
enantiomer
fluorohydrin
access
commerci
avail
otrityl
glycidol
reaction
potassium
hydrogen
difluorid
present
work
investig
fluorin
r
diisopropylphosphoryl
methoxi
propanol
compound
utilis
laboratori
common
start
materi
prepar
phosphonomethoxi
propyl
deriv
synthon
access
larg
scale
threestep
synthesi
trityloxymethyl
oxiran
scheme
first
experi
fluorin
carri
via
previou
activ
hydroxyl
group
eg
reaction
ptoluenesulphonyl
chlorid
although
reaction
tosyl
form
way
tetrabutylammonium
fluorid
proceed
satisfactorili
total
prepar
yield
fluoro
deriv
high
complic
labori
isol
purif
tosyl
intermedi
altern
way
direct
fluorin
hydroxi
deriv
approach
never
explor
area
anp
synthon
whose
synthesi
usual
perform
largescal
multistep
process
without
isol
intermedi
fluorin
reagent
gener
use
substitut
hydroxi
group
dast
olah
reagent
fluoroalkylamin
reagent
recent
describ
fluorid
nucleophil
fluorin
reagent
prepar
thymidin
phosphorylas
inhibitor
r
phosphonomethoxi
propyl
thymin
fpmpt
unlik
variou
strongli
corros
reagent
eg
dast
deoxofluor
fluorid
stabl
littl
moisturesensit
easi
handl
use
direct
fluorin
anp
known
sever
exampl
mention
fpmpt
synthesi
appropri
start
materi
phosphonomethoxi
propyl
deriv
thymin
reason
fluorin
sensit
presenc
acid
hydrogen
atom
start
molecul
exampl
perform
reaction
diisopropyl
ester
hpmpt
contain
nh
posit
thymin
moieti
result
elimin
basic
condit
result
sixmemb
ring
closur
sidechain
hydroxi
group
similarli
fluorin
method
also
fail
cytosin
deriv
hpmpc
import
aspect
synthes
fluorid
select
reaction
condit
base
solvent
base
good
proton
acceptor
low
nucleophil
moder
basic
avoid
elimin
prepar
fluoro
deriv
r
diisopropylphosphoryl
methoxi
propanol
chose
nethylpiperidin
nep
dbu
reaction
nep
report
provid
better
result
synthes
fluorin
nucleosid
prepar
fpmp
precursor
proceed
satisfactori
use
dbu
reaction
carri
toluen
initi
room
temperatur
although
yield
reaction
rate
slow
signific
decreas
reaction
time
achiev
heat
c
full
convers
observ
dbu
ad
hour
h
cours
fluorin
reaction
nep
wors
requir
excess
perfluorobutanesulphonyl
fluorid
convers
h
final
fpmp
synthon
diisopropoxyphosphoryl
methoxi
ptoluenesulphon
obtain
remov
benzyl
group
via
catalyt
hydrogen
give
intermedi
subject
tosyl
scheme
condens
diisopropoxyphosphoryl
methoxi
ptoluenesulphon
sodium
salt
perform
heat
n
ndimethylformamid
catalyt
amount
caesium
carbon
reaction
afford
mixtur
n
regioisom
whose
ratio
depend
reaction
time
scheme
highest
regioselect
observ
sodium
salt
heat
phosphon
c
h
case
n
detect
prepar
yield
low
extens
reaction
time
result
increas
format
isom
h
c
ratio
regioisom
prepar
yield
regard
observ
obviou
alkyl
balanc
process
desir
n
isom
form
product
possess
kinet
stabil
final
product
free
phosphon
acid
obtain
diisopropyl
ester
standard
procedur
deprotect
bromotrimethylsilan
follow
hydrolysi
order
also
prodrug
form
avail
antivir
screen
select
phosphoramid
prodrug
synthesi
perform
modifi
procedur
origin
develop
jansa
base
reaction
diisopropyl
ester
bromotrimethylsilan
first
give
intermediari
bi
trimethylsilyl
ester
intermedi
convert
without
isol
desir
bi
amid
reaction
appropri
amino
acid
ester
activ
dithiopyridin
triphenylphosphin
scheme
direct
reaction
ethyl
lalanin
triphenylphosphin
success
give
desir
bi
amid
low
yield
togeth
number
byproduct
signific
problem
compound
hydrolyt
instabl
substanti
compromis
pharmaceut
potenti
instabl
caus
electron
defici
posit
triazin
ring
imineresembl
carbon
could
easili
attack
nucleophil
eg
hydroxyl
ion
accompani
cleavag
ring
hand
convers
compound
counterpart
sp
hybridisi
carbon
ch
posit
lead
compound
hydrolyt
stabl
nucleosid
modifi
way
eg
still
preserv
antitumor
hypomethyl
activ
lower
comparison
origin
deriv
compound
less
toxic
field
anp
previous
report
deriv
fig
compound
preserv
antidna
viru
activ
albeit
lower
nevertheless
contrast
also
exhibit
inhibitori
activ
hcv
replic
hydrolyt
stabl
transform
correspond
deriv
carri
level
diisopropyl
ester
via
catalyt
hydrogen
step
follow
deprotect
ester
group
intermedi
use
bromotrimethylsilan
scheme
guanidin
group
moieti
provid
uniqu
opportun
prepar
imidazo
triazin
deriv
e
compound
four
hydrogenbond
site
bear
annel
imidazol
ring
analogu
form
reaction
deriv
appropri
carbonyl
compound
describ
coupl
phosphon
variou
scheme
although
desir
annel
product
form
case
imidazol
imino
group
found
sensit
toward
alkyl
compound
treat
alkyl
byproduct
isol
togeth
product
hand
afford
alkyl
product
surprisingli
enough
seriou
problem
occur
deprotect
diisopropyl
ester
group
final
phosphon
acid
usual
way
use
bromotrimethylsilan
complet
fail
lead
mixtur
decomposit
product
anoth
possibl
microwaveassist
acid
hydrolysi
method
transform
phosphon
ester
free
anp
origin
develop
iocb
jansa
method
usual
clean
isol
product
easi
experi
hydrolys
two
equival
hcl
c
min
microwav
irradi
unfortun
ring
triazin
moieti
open
methylen
group
hydrolyt
split
indic
destabilis
ring
consequ
imidazoletriazin
annel
hand
observ
earlier
anp
better
stabil
case
phosphon
function
mask
appropri
prodrug
group
take
account
find
select
anoth
synthet
strategi
start
bi
amid
prodrug
compound
easili
reduc
correspond
form
subject
condens
reaction
form
desir
annel
structur
prodrug
form
scheme
way
jansa
method
transform
phosphon
ester
phosphoramid
nt
take
place
may
caus
presenc
acet
acid
structur
condens
reaction
use
aldrithiol
triphenylphosphin
known
proceed
via
cyclic
intermedi
whose
format
requir
proton
come
nucleophil
eg
amino
acid
ester
possibl
acet
acid
preferenti
proton
pyridin
unit
activ
nucleophil
phosphon
unit
besid
fpmp
deriv
also
work
synthes
anp
bear
gemdifluorin
arrang
method
develop
laboratori
purin
gemdifluorin
anp
unfortun
effort
fail
instabl
triazin
ring
deprotect
phosphon
ester
group
bromotrimethylsilan
well
microwav
condit
hand
anp
trifluoromethyl
arrang
known
stabl
toward
lewi
acid
therefor
phosphon
could
prepar
quit
easili
scheme
first
approxim
compound
prepar
racem
use
cheap
easili
access
trifluoromethyloxiran
approach
suffici
evalu
true
biolog
potenti
compound
biolog
activ
sought
pure
enantiom
would
subsequ
synthesis
synthesi
base
treatment
trifluoromethyloxiran
follow
reaction
form
hydroxi
deriv
appropri
phosphon
synthon
give
desir
phosphon
form
ester
purpos
two
phosphon
synthon
investig
reaction
diisopropyl
tosyloxymethanephosphon
sodium
hydrid
afford
low
yield
convers
increas
substanti
reactiv
diisopropyl
bromomethanephosphon
sodium
tertbutoxid
use
synthesis
sidechain
fluorin
analogu
evalu
inhibitori
activ
wide
rang
dna
rna
virus
human
embryon
lung
valu
three
time
higher
refer
antihcmv
drug
ganciclovir
without
display
cytotox
hel
cell
highest
concentr
test
mm
compound
prove
significantli
less
activ
wildtyp
strain
vzv
refer
drug
acyclovir
contrast
acyclovir
remain
activ
tkdefici
virus
deriv
prove
inact
dna
virus
vaccinia
viru
poxviru
adenovirus
compound
show
margin
activ
herpesvirus
adenoviru
ec
valu
rang
mm
sever
synthet
strategi
sidechain
fluorin
acycl
nucleotid
analogu
bear
imidazo
triazin
base
moieti
develop
highli
polar
free
phosphon
acid
transform
amid
prodrug
new
compound
subject
investig
biolog
antivir
activ
except
fpmp
diisopropyl
ester
activ
human
cytomegaloviru
herpesvirus
neglig
activ
herpesvirus
adenoviru
none
newli
synthesis
acycl
nucleosid
analogu
anp
exhibit
antivir
activ
unless
state
otherwis
solvent
evapor
c
kpa
compound
dri
pa
column
chromatographi
perform
silica
gel
mm
fluka
analyt
tlc
perform
silica
gel
f
plate
merck
solvent
system
chloroformmethanol
chloroformmethanol
ethyl
acetateacetoneethanolwat
aq
ammoniawat
standard
chemic
ionexchang
resin
purchas
sigmaaldrich
czech
republ
synthet
precursor
prepar
tritylglycidyl
ether
accord
ref
sodium
salt
prepar
treatment
sodium
methoxid
accord
ref
diisopropyl
bromomethylphosphon
purchas
alfa
aesar
trifluoromethyloxiran
purchas
fluorochem
wesley
street
old
glossop
anhydr
solvent
purchas
sigmaaldrich
penta
czech
republ
tabl
vitro
antivir
activ
fluorin
deriv
dna
virus
compar
refer
antivir
drug
acyclovir
acv
brivudin
bvdu
ganciclovir
gcv
cidofovir
cdv
solut
g
mmol
acetonitril
ml
cool
c
triethylamin
ml
mol
tscl
g
mmol
dmap
mg
ad
mixtur
stir
room
temperatur
h
full
convers
concentr
vacuo
residu
partit
ether
water
ml
organ
layer
dri
magnesium
sulphat
evapor
obtain
materi
use
next
step
without
purif
yield
g
yellow
oil
h
c
nmr
data
ident
report
ref
mixtur
dbu
ml
mmol
nethylpyrrolidin
mmol
fluorid
mg
mmol
stir
toluen
ml
room
temperatur
min
solut
mg
mmol
toluen
ml
ad
result
mixtur
heat
c
h
tlc
control
ethyl
acet
mixtur
evapor
residu
chromatograph
silica
gel
column
gradient
hexan
hexan
e
ethyl
acet
yield
mg
reaction
dbu
mg
reaction
nep
yellow
oil
h
c
nmr
data
ident
describ
method
solut
g
mmol
methanol
ml
hydrogen
high
pressur
autoclav
atm
palladium
charcoal
g
suspend
water
ml
h
mixtur
filter
celit
pad
filtrat
mixtur
g
mmol
sodium
salt
mg
mmol
caesium
carbon
mg
mmol
dimethylformamid
ml
heat
c
h
mixtur
concentr
vacuo
residu
coevapor
toluen
ml
chromatograph
prepar
tlc
plate
dichloromethanemethanol
yield
mg
white
amorph
solid
r
f
yield
mg
yellowish
oil
r
f
ir
ccl
n
max
bromotrimethylsilan
ml
mmol
ad
solut
mg
mmol
acetonitril
ml
mixtur
stir
room
temperatur
overnight
evapor
residu
coevapor
water
ml
residu
dissolv
water
ml
appli
onto
column
dowex
acet
form
ion
exchang
wash
water
gradient
acet
acid
final
formic
acid
appropri
uv
absorb
fraction
evapor
residu
coevapor
methanol
ml
toluen
ml
product
final
lyophilis
water
yield
mg
bromotrimethylsilan
ml
mmol
stir
room
temperatur
overnight
evapor
argon
residu
coevapor
toluen
ml
residu
ethyl
lalanin
mg
mmol
dissolv
pyridin
ml
triethylamin
ml
solut
warm
c
anoth
solut
consist
mg
mmol
triphenylphosphin
pyridin
ml
ad
result
mixtur
heat
c
h
stir
room
temperatur
overnight
mixtur
evapor
residu
chromatograph
silica
gel
gradient
methanol
chloroform
yield
compound
mg
mmol
hydrogen
acet
acid
ml
palladium
charcoal
mg
atmospher
pressur
tlc
control
h
mixtur
filter
celit
pad
filtrat
evapor
residu
coevapor
toluen
ml
methanol
ml
hexan
ml
mixtur
mg
mmol
acetonitril
ml
bromotrimethylsilan
ml
mmol
stir
room
temperatur
overnight
evapor
residu
coevapor
acetonitril
ml
water
ml
residu
extract
etherwat
ml
ethyl
acetatewat
ml
etherwat
ml
aqueou
layer
evapor
residu
coevapor
methanol
ml
toluen
ml
ethyl
acet
ml
final
purif
perform
revers
phase
column
water
product
lyophilis
water
yield
mg
yellowish
foam
mixtur
mmol
bromoacetophenon
mmol
sodium
bicarbon
mg
mmol
dmf
ml
stir
room
temperatur
h
mixtur
evapor
residu
chromatograph
prepar
tlc
plate
system
mention
compound
evalu
differ
herpesvirus
includ
herp
simplex
viru
type
strain
ko
thymidin
kinasedefici
tk
e
ko
strain
resist
acv
acv
r
herp
simplex
viru
type
strain
g
varicellazost
viru
vzv
strain
oka
tk
tk
e
vzv
strain
human
cytomegaloviru
hcmv
strain
davi
well
vaccinia
viru
vesicular
stomat
viru
viru
sindbi
viru
coxsacki
viru
punta
toro
viru
respiratori
syncyti
viru
rsv
felin
coronoviru
fipv
influenza
viru
subtyp
influenza
b
viru
antivir
assay
base
inhibit
virusinduc
cytopath
plaqu
format
human
embryon
lung
hel
fibroblast
african
green
monkey
kidney
cell
vero
human
epitheli
cervix
carcinoma
cell
hela
crandellre
felin
kidney
cell
crfk
madin
darbi
canin
kidney
cell
mdck
confluent
cell
cultur
microtit
plate
inocul
ccid
viru
ccid
viru
dose
infect
cell
cultur
plaqu
form
unit
pfu
cell
cultur
incub
presenc
vari
concentr
test
compound
viral
cytopath
plaqu
format
vzv
record
soon
reach
complet
control
virusinfect
cell
cultur
treat
test
compound
antivir
activ
express
ec
compound
concentr
requir
reduc
virusinduc
cytopath
viral
plaqu
format
cytotox
test
compound
express
minimum
cytotox
concentr
mcc
compound
concentr
caus
microscop
detect
alter
cell
morpholog
altern
cytostat
activ
test
compound
measur
base
inhibit
cell
growth
hel
cell
seed
rate
cellswel
microtit
plate
allow
prolifer
h
subsequ
medium
contain
differ
concentr
test
compound
ad
three
day
incub
c
cell
number
determin
coulter
counter
cytostat
concentr
calcul
cc
compound
concentr
requir
reduc
cell
prolifer
rel
number
cell
untreat
control
author
declar
conflict
interest
